Bone Cancer Ablation
Prof. Afshin Gangi
Prof. Afshin Gangi is Europe's leading voice in Bone cryoablation and is known throughout the world. He operates in both London and Strasbourg and has a special interest in spinal disease.
Benefits of cancer ablation
- Shorter hospital stay
- Return to work quicker
- Preserves normal tissue better than surgical techniques
- Incisionless and scarless
Bone tumours may arise from the bone itself (primary bone tumours) or from other organs (secondary bone tumours). Secondary disease commonly originates from lung breast kidney thyroid and prostate cancers.
Cryoablation has been successfully used both for disease control and symptom palliation. Its use is increasing rapidly across the world. The focal destruction of bone cancer allows for more of the normal bony architecture to be preserved. This has profound benefits for preserving mobility and strength.
Primary Bone tumours can be successfully treated as can slow growing secondary tumours that are either solitary or multiple. Diffuse bony spread is better treated with systemic therapy.
Unfortunately some cancers spread to the bone where they can cause intractable pain. Cryoablation appears to be particularly effective in treating this pain. Uniquely, Cryo can destroy bone tumours and with a combination of "reconstructive cement" can preserve bone strength.
How do I proceed?
Referrals for Bone ablation are better coming directly from your oncologist or cancer care team. Patients with cancer in other organs or patients with effusions are unlikely to be suitable as systemic therapy is the appropriate treatment. If in doubt contact your oncologist.
The decision to ablate depends very much on the exact site and nature of your disease. Decisions to ablate or operate are taken by the cancer team, not by individuals. It is also dependant on your overall health as ablation is a hospital procedure that requires either general anaesthesia or deep sedation.
The procedure is performed under general anaesthetic to help with the precise positioning of the cryoprobes. When appropriate tumours are targeted most patients experience a dramatic improvement in pain control. A follow up scan is performed about 10 days after the treatment to assess the outcome.